Abexome Biosciences Profile
Key Indicators
- Authorised Capital ₹ 1.60 Cr
as on 17-12-2024
- Paid Up Capital ₹ 1.15 Cr
as on 17-12-2024
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.05 Cr
as on 17-12-2024
- Revenue %
(FY 2020)
- Profit -12.43%
(FY 2020)
- Ebitda 12.78%
(FY 2020)
- Net Worth -4.40%
(FY 2020)
- Total Assets -3.38%
(FY 2020)
About Abexome Biosciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.60 Cr and a paid-up capital of Rs 1.15 Cr.
The company has closed loans amounting to ₹1.05 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Suri Venkatachalam and Nandan Sastry serve as directors at the Company.
- CIN/LLPIN
U73100KA2007PTC041611
- Company No.
041611
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Feb 2007
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Abexome Biosciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suri Venkatachalam  | Director | 01-Feb-2007 | Current |
| Nandan Sastry | Director | 22-May-2018 | Current |
Financial Performance and Corporate Structure Insights of Abexome Biosciences.
Abexome Biosciences Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 12.43% decrease in profit. The company's net worth dipped by a decrease of 4.4%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abexome Biosciences?
In 2019, Abexome Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Foundation For Neglected Disease ResearchActive 10 years 3 monthsSuri Venkatachalam is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Department Of Biotechnology Creation Date: 30 May 2011 | ₹1.05 Cr | Satisfied |
How Many Employees Work at Abexome Biosciences?
Abexome Biosciences has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abexome Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abexome Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
